Drug safety surveillance in China and other countries: A review and comparison

Value in Health

Volumn 11, Issue SUPPL. 1, 2008, Pages

  Du, Wenmin ^a   Guo, Jeff J ^b,c   Jing, Yonghua ^b   Li, Xing ^b   Kelton, Christina M L ^c  

^a Shanghai Municipal Food and Drug Administration   (China)

^b UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Adverse drug reaction; China; Drug safety; Surveillance

Indexed keywords

ARMILLARISNI A; CERIVASTATIN; CISAPRIDE; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE GLUCOSE; DIETHYLENE GLYCOL; HEARTLEAF HOUTTUYINIA EXTRACT; HERBACEOUS AGENT; ROFECOXIB; TERFENADINE; TROGLITAZONE; UNCLASSIFIED DRUG; XINFU; YU XING CAO;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ANAPHYLACTIC SHOCK; CHINA; CLINICAL PRACTICE; COMPARATIVE STUDY; CONFERENCE PAPER; CONTINUOUS INFUSION; CULTURAL FACTOR; DEATH; DIARRHEA; DRUG FATALITY; DRUG MARKETING; DRUG MONITORING; DRUG SAFETY; EUROPE; FOOD AND DRUG ADMINISTRATION; HEARTLEAF HOUTTUYINIA; HERB; HUMAN; KIDNEY PAIN; LAW; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; THORAX DISEASE; UNITED STATES; VOMITING;

EID: 41749111808     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00377.x     Document Type: Conference Paper

References (30)

1. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc 2001 41 : 192 9.
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998 279 : 1200 5.
3. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005 365 : 475 81.
4. Center for Drug Re-evaluation. State food and drug administration of China. ADR reporting and monitoring in China. Available from: http://www.who-umc.org [Accessed October 31, 2006].
5. Zhou Y, Miller V, Hogan M, Callahan L. An overview of adverse drug reaction monitoring in China. Int J Pharm Med 2006 20 : 79 85.
6. Center for Drug Re-evaluation. SFDA. Available from: http://www.cdr.gov. cn/index.jsp [Accessed October 31, 2006].
7. Hou YL. ADR reports in China reached anew peak in 2005. China Pharm News 2006 : Section A1.
8. Clinical Safety Data Management. Definitions and Standards for Expedited Reporting. London : European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, 1995. Available from: http://www.emea.eu.int/ pdfs/human/ich [Accessed October 31, 2006].
9. Chinese Medical Institute & Register. Code of Conduct and Good Practice. Available from: http://www.cmir.org.uk [Accessed April 12, 2007].
10. State Food and Drug Administration of China (SFDA). Drug administration law of the People's Republic of China. Available from: http://www.sfda.gov.cn/ cmsweb/webportal [Accessed October 31, 2006].
11. China Ministry of Health & SFDA. Regulation for the administration of adverse drug reaction report and monitoring. Available from: http://www.cdr.gov.cn/doc/content [Accessed October 31, 2006].
12. State Food and Drug Administration of China. Laws and regulations. Available from: http://www.sfda.gov.cn/cmsweb/webportal [Accessed October 31, 2006].
13. Cheng RL. Needs for post-marketing evaluations in China. Chin J Pharmacovigilance 2005 2 : 220 5.
14. The network of ADRs monitoring in China. Available from: http://www.adr.gov.cn [Accessed October 31, 2006].
15. Met Q, Zeng C. On the event of 'Exigent Withdrawal of Houttuynia Cordata Injection'. China Pharm 2006 17 : 1124 6.
16. Center of Drug Reevaluation, SFDA. Questions and answers about the temporally withdrawal of houttuynia herb injections from the market. Available from: http://www.cdr.gov.cn/docbase/infodata [Accessed October 31, 2006].
17. Wang Y, Tang Z. The analysis of ADRs related to houttuynia herb injections. Chin J New Drugs 2006 15 : 739 41.
18. Center of Drug Reevaluation, SFDA. Warning about the ADRs related to houttuynia herb injections. Available from: http://www.cdr.gov.cn/doc/ [Accessed October 31, 2006].
19. Center of Drug Reevaluation, SFDA. The new developments and progressions of ADR monitoring and regulations in China. Available from: http://www.cdr.gov. cn/ [Accessed October 31, 2006].
20. State Food and Drug Administration of China. The notice about the temporally withdrawal of houttuynia herb injections from the market. Available from: http://www.sfda.gov.cn/eng/ [Accessed October 31, 2006].
21. State Food and Drug Administration of China. The notice about the regulations of the seven houttuynia herb injections. Available from: http://www.sfda.gov.cn/eng/ [Accessed October 31, 2006].
22. State Food and Drug Administration of China. The National report about Xinfu ADRs by August 13, 2006. Available from: Http://News.Sohu.Com/S2006/Xinfu/ [Accessed September 22, 2006].
23. China Daily. Drug that has sickened dozens banned. 2006-08-04. Available from: http://www.chinadaily.com.cn/china/2006-08/04 [Accessed September 22, 2006].
24. State Food and Drug Administration of China. The investigation results of clindamycin phosphate glucose injection produced by the Anhui Huayuan Pharmacy Co. Available from: http://www.sfda.gov.cn/cmsweb/webportal [Accessed October 31, 2006].
25. Zamiska N, Hanting T. China government cited in medicine probe. Wall Street Journal. 2007-02-09. Available from: http://online.wsj.com [Accessed April 8, 2007].
26. United States FDA. FDA issues final risk minimization guidance. Available from: http://www.fda.gov/bbs/topics/news/2005 [Accessed October 31, 2006].
27. FDA. Premarketing risk assessment guidance. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
28. FDA. Development and use of risk minimization action plans. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
29. FDA. Good pharmacovigilance practices and pharmacoepidemiologic assessment. Available from: http://www.fda.gov/cder/guidance [Accessed October 31, 2006].
30. European Medicine Agency (EMeA). Guideline on risk management systems for medicinal products for human use. Available from: http://www.emea.eu.int/pdfs/ human [Accessed October 31, 2006].